Philips Respironics Recall, Explained Neutrally — and Your Data

Few CPAP events have caused as much confusion and worry as the 2021 Philips Respironics recall. If you owned a DreamStation or a Philips BiPAP, you likely got a letter, a registration request, and a long wait — followed by conflicting headlines about the foam in your replacement machine. This guide lays out what actually happened, in order, without spin, and then turns to the question that matters most to many readers: what the recall means for your therapy data if you ended up on a different machine.

The June 2021 voluntary recall (PE-PUR foam)

In June 2021, Philips Respironics issued a voluntary recall covering millions of sleep and respiratory devices — including many CPAP and BiPAP machines and certain mechanical ventilators. The problem was the PE-PUR foam (polyester-based polyurethane), a sound-abatement material placed inside the device to make it quieter.

Over time, and especially in hot, humid, or ozone-exposed conditions, that foam could degrade. Two concerns drove the recall:

• Particulate exposure — small black foam particles could break off and travel into the air pathway.
• Off-gassing — the degrading foam could release certain chemicals (volatile organic compounds, or VOCs) into the airstream.

The recall swept in many popular machines, most notably the original DreamStation 1 line. (If you still use a recalled DreamStation 1, our DreamStation 1 & System One data guide covers reading its SD card.) Philips advised patients to talk with their physicians about whether to continue therapy or pause it — a difficult call, because stopping CPAP carries its own real risks, and untreated sleep apnea is associated with serious cardiovascular harm. Many clinicians recommended that patients keep treating while waiting for a remedy, weighing the known dangers of untreated apnea against an uncertain foam risk.

The silicone-foam replacement devices

Philips' remediation plan was to repair or replace affected devices, swapping the problematic PE-PUR foam for a silicone-based foam that does not degrade the same way. For most CPAP users, this meant either a rework of their existing machine or a brand-new replacement unit shipped to their door.

The silicone foam solved the original particulate-degradation issue. But it raised a new round of questions that deserve careful, accurate handling — because this is exactly where headlines and reality diverged.

What independent testing and the FDA actually said about VOCs

Here is the part that gets misreported most often, so it's worth stating precisely:

• An FDA inspection report and independent laboratory tests — the latter commissioned by Philips itself — raised concerns that the silicone replacement foam could emit volatile organic compounds (VOCs), including formaldehyde.
• The FDA did not issue its own finding that the foam releases these chemicals. What happened is more specific: after learning that a silicone-foam device sold outside the United States failed one VOC test, the FDA requested additional independent safety testing.
• While that testing was pending, the FDA advised patients to keep using their repaired or replacement devices. The agency framed this as the cautious choice, given the known risks of going untreated.
• Philips maintains that detected VOC levels, including formaldehyde, stayed below applicable toxicological thresholds. Some independent experts dispute which thresholds should apply.

In plain terms: this was a "more testing requested, keep using your device for now" situation — not an FDA declaration that your replacement machine is unsafe. For any decision about your specific health, lean on FDA primary communications and your own clinician rather than on retailer blog posts, which frequently overstate the FDA's role.

The separate 2023 DreamStation 2 safety communication

It's easy to conflate two distinct events, so let's separate them clearly.

The DreamStation 2 (DS2) was the newer machine — in many cases the very unit sent out as a replacement, or bought fresh. In 2023, the FDA issued a separate safety communication about reports of the DS2 overheating, which in some cases involved smoke, fire, or burns. This was a different problem from the foam issue entirely, and it applied to a different device generation.

If you're on a DS2 and want to read its therapy data, there's an extra wrinkle worth knowing: the DreamStation 2's SD-card data is encrypted and is not readable by OSCAR or most third-party tools. SomniCharts is one of the tools that does support DS2 data — our DreamStation 2 encrypted-data guide walks through the options.

Registration deadlines and remediation status

The remediation program ran for years and eventually wound down on a fixed timeline:

• US and Canada registration closed December 31, 2024. After that date, new claims for repair or replacement under the recall program were generally no longer accepted in those regions.
• Globally, Philips has reported that roughly 99% of registered devices were remediated — repaired, replaced, or otherwise addressed.

The practical upshot for most users today: the active remediation window has passed. If your device was registered and handled, you're likely on a silicone-foam machine, a DreamStation 2, or a different brand entirely. If you missed the window, your path forward is a conversation with your equipment provider (DME) and clinician about a current-generation device.

Displaced users and reading data on a new machine

The recall didn't just replace foam — it rerouted a lot of people onto different equipment. Some got a DreamStation 2. Many switched brands altogether, often to a ResMed AirSense, while supply was tight or because their provider made the change. That shuffle created a quiet, lasting problem: a broken data history.

Here's why that matters. Your CPAP's value isn't in any single night — single-night numbers are noise. The real signal lives in trends over weeks and months: is your residual AHI stable, is your leak creeping up, is your pressure demand changing? When you move from a recalled DreamStation to a new machine, that continuity usually snaps. Each manufacturer's app shows only its own devices, and they don't talk to each other:

• ResMed's myAir shows only ResMed machines, with a single 0–100 score weighted heavily toward usage hours — no per-event-type, leak, or flow-limitation detail.
• Philips' DreamMapper app shut down in January 2026, stranding the history of users who relied on it.

So a recall-displaced user can easily end up with two or three disconnected slices of their own therapy story. (Our guide to myAir and DreamMapper limitations goes deeper on why the manufacturer apps fall short.)

This is where a vendor-neutral tool earns its place. SomniCharts imports ResMed, Philips Respironics (including the encrypted DreamStation 2), and Löwenstein prisma data, then explains it in plain language automatically — so you can keep one continuous history across the switch instead of starting over on a new app. If you moved machines because of the recall, see keeping your data history across vendors for how to stitch the timeline back together.

A few things to keep in mind as you compare old and new data side by side:

• Leak numbers aren't directly comparable across brands. ResMed reports excess leak (its threshold is 24 L/min at the 95th percentile), while Philips reports total leak — different baselines, so don't read a raw number jump as a real change. See CPAP leak rate explained.
• AHI can shift after a machine change for benign reasons (different algorithm, different comfort settings). The general benchmark for effective therapy is a residual AHI below 5 events per hour; some clinicians aim lower when it's comfortably achievable, but targets are individualized with your provider. More in what's a good AHI on CPAP.
• Watch for central (clear-airway) events. CPAP reliably splints the airway open for obstructive apneas, but it does not directly correct the breathing-drive instability behind central events. A rise in central events after a switch can reflect treatment-emergent central sleep apnea, which often settles on its own within weeks to a few months on continued CPAP — but persistent cases deserve a clinician's review. Never raise your own pressure to chase central events.

The recall was disruptive, but your data doesn't have to be a casualty of it. Whatever machine you landed on, the goal is the same: an unbroken, readable record you can bring to your clinician. For the bigger picture on the devices themselves, return to our CPAP Machines & Devices hub.